Management of Thrombocytopenia in Patients with Chronic Liver Disease
Thrombocytopenia is the most common hematologic complication associated with chronic liver disease (CLD) with important clinical implications. While the mechanisms for thrombocytopenia are multifactorial, platelet sequestration in the spleen and decreased thrombopoietin (TPO) production are the main mechanisms in patients with CLD.
This review outlines the current treatment options for thrombocytopenia in patients with CLD, explores their limitations, and proposes a revised treatment algorithm for the management of thrombocytopenia in this patient group.
A PubMed search of the literature was undertaken with search terms focused on CLD and thrombocytopenia.
Until now, the standard-of-care treatment in these patients has been the use of platelet transfusions either prophylactically or periprocedurally to control bleeding. Treatment options, such as splenic artery embolization and splenectomy, are invasive, and their utility is limited by significant complications. The US Food and Drug Administration recently approved 2 s-generation TPO-receptor agonists, avatrombopag and lusutrombopag, as safe and effective therapies for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure.
The addition of avatrombopag and lusutrombopag offers physicians an alternative to platelet transfusions in patients with CLD who have to undergo medical/dental procedures that could potentially put them at an increased risk of bleeding. There are several other drugs in the research pipeline at various stages of development, including a new class of monoclonal antibodies that can bind to and activate TPO-receptor agonists. The outlook for treatment choices for thrombocytopenia in patients with liver disease is promising.
KeywordsChronic liver disease Cirrhosis Thrombocytopenia Thrombopoietin receptor agonists Platelets transfusion Treatment algorithm
Assistance with research, drafting of manuscript, and editorial support was provided by BioCentric, Inc.
SS and RSB were involved in study concept and design; they contributed to acquisition of data; they analyzed and interpreted the data; they contributed to critical revision of the manuscript for important intellectual content; they contributed to statistical analysis (not applicable), provided administrative, technical, or material support, and supervised the study. SS, RSB and BioCentric, Inc., drafted the manuscript.
Compliance with ethical standards
Conflict of interest
The authors of this manuscript have no conflicts of interest to disclose.
- 1.Thrombocytopenia. National Heart, Lung, and Blood Institute website. www.nhlbi.nih.gov/health-topics/thrombocytopenia. Accessed August 10, 2018.
- 2.Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician. 2012;85:612–622.Google Scholar
- 5.Chronic liver disease and cirrhosis. Centers for Disease Control and Prevention website. www.cdc.gov/nchs/fastats/liver-disease.htm. Updated October 6, 2016. Accessed August 10, 2018.
- 10.Demetri GD. Targeted approaches for the treatment of thrombocytopenia. Oncologist. 2001;6:15–23. https://doi.org/10.1634/theoncologist.6-suppl_5-15.CrossRefGoogle Scholar
- 23.Beutler E. Platelet transfusions: the 20,000/microL trigger. Blood. 1993;81:1411–1413.Google Scholar
- 26.Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci. 2002;17:6–10.Google Scholar
- 27.Nplate [package insert]. Thousand Oaks, CA: Amgen Inc; 2018.Google Scholar
- 29.Buccoliero G, Urbano T, Mazza P, Resta F, Pisconti S. Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis C virus infection: a new option for clinicians? New Microbiol. 2014;37:97–101.Google Scholar
- 30.Promacta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.Google Scholar
- 33.Doptelet [package insert]. Durham, NC: Dova Pharmaceuticals Inc; 2018.Google Scholar
- 35.Mulpleta [package insert]. Florham Park, NJ: Shionogi Inc.; 2018.Google Scholar
- 42.Patel IJ, Davidson JC, Nikolic B, et al. Standards of practice committee, with cardiovascular and interventional radiological society of Europe (CIRSE) endorsement. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image guided interventions. J Vasc Interv Radiol. 2012;23:727–736. https://doi.org/10.1016/j.jvir.2012.02.012.CrossRefGoogle Scholar
- 44.Tillmann HL, McHutchison JG. Use of thrombopoietic agents for the thrombocytopenia of liver disease. Semin Hematol. 2010;47:266–273. https://doi.org/10.1053/j.seminhematol.2010.04.003.CrossRefGoogle Scholar
- 46.Mitchell O, Feldman DM, Diakow M, et al. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39–50.Google Scholar